Pioglitazone Accord 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IA/0022 
A.7 - Administrative change - Deletion of 
11/01/2022 
Annex II and 
manufacturing sites 
PL 
II/0020 
Update of the Risk Management Plan (RMP) for the 
26/11/2020 
09/12/2021 
Annex II 
n/a 
removal of safety concerns and additional risk 
minimisation measures (ARRM) as per summary of 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
RMP of Glidipion (pioglitazone; published on 20-Jul-
2020), and content adapted to the new GVP Module 
V (Rev.2). Product information Annex II is amended 
accordingly. 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
IAIN/0021 
B.II.b.2.c.1 - Change to importer, batch release 
25/11/2020 
09/12/2021 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IAIN/0018/G 
This was an application for a group of variations. 
25/02/2019 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
Page 2/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
T/0017 
Transfer of Marketing Authorisation 
28/01/2019 
14/02/2019 
SmPC, 
Labelling and 
PL 
IAIN/0016 
B.II.b.2.c.1 - Change to importer, batch release 
27/09/2018 
14/02/2019 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
II/0015/G 
This was an application for a group of variations. 
19/04/2018 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
B.II.b.5.z - Change to in-process tests or limits 
Page 3/7 
 
 
 
 
 
 
 
 
 
 
 
 
applied during the manufacture of the finished 
product - Other variation 
B.II.d.1.e - Change in the specification parameters 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
IB/0014 
C.I.11.z - Introduction of, or change(s) to, the 
05/04/2017 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
R/0011 
Renewal of the marketing authorisation. 
13/10/2016 
05/12/2016 
Based on the review of data on quality, safety and efficacy, 
the CHMP considered that the benefit-risk balance of 
Pioglitazone Accord in the approved indications remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IAIN/0013/G 
This was an application for a group of variations. 
27/10/2016 
n/a 
B.III.1.a.1 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
B.III.2.a.1 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - AS 
IB/0012/G 
This was an application for a group of variations. 
28/06/2016 
05/12/2016 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0010 
B.III.1.a.3 - Submission of a new/updated or 
15/01/2016 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IA/0008 
B.II.b.4.a - Change in the batch size (including batch 
02/12/2014 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
IB/0007 
To update the section 2, 4.1, 4.2, 4.3, 4.4, 4.6, 4.7, 
10/10/2014 
07/11/2014 
SmPC, Annex 
4.8, 5.1, 5.3, 6.6 of SmPC, Annex II and Annex IIIB 
II and PL 
section 1, 2, 3, 4, 5, 6, in line with originator product 
information and to add indication no longer under 
patent. Furthermore, annexes were brought in line 
with the latest QRD template version. All changes 
made are in order to harmonise text with the 
originator. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0006 
C.I.2.a - Change in the SPC, Labelling or PL of a 
12/12/2013 
07/11/2014 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0005 
C.I.2.a - Change in the SPC, Labelling or PL of a 
12/11/2013 
20/12/2013 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
IAIN/0004 
C.I.8.a - Introduction of or changes to a summary of 
30/08/2013 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IAIN/0003 
A.1 - Administrative change - Change in the name 
22/01/2013 
20/12/2013 
SmPC, 
and/or address of the MAH 
N/0002 
Minor change in labelling or package leaflet not 
18/06/2012 
20/12/2013 
connected with the SPC (Art. 61.3 Notification) 
IB/0001 
B.II.b.5.z - Change to in-process tests or limits 
12/06/2012 
n/a 
applied during the manufacture of the finished 
Labelling and 
PL 
PL 
Page 6/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Other variation 
Page 7/7 
 
 
 
 
 
 
 
